12 Recruiting Studies Using Mirdametinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Mirdametinib
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
📍 University of Alabama at Birmingham/Children's of Alabama — Birmingham, Alabama
Plexiform Neurofibroma
View Study & Checklist ➔Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
📍 Childrens of Alabama — Birmingham, Alabama
Neurofibromatosis 1 (NF1)
View Study & Checklist ➔Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
📍 Alberta Children's Hospital — Calgary, Alberta
Pediatric Low-grade Glioma
View Study & Checklist ➔A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Well Differentiated Liposarcoma
View Study & Checklist ➔SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
📍 St. Jude Children's Research Hospital — Memphis, Tennessee
Low-Grade Glioma
View Study & Checklist ➔Mirdametinib in Patients With Advanced NF1-mutant Melanoma
📍 California Pacific Medical Center - Sutter Health — San Francisco, California
Advanced Unresectable Melanoma
View Study & Checklist ➔A Study of Mirdametinib in People With Central Nervous System Tumors
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Central Nervous System Tumors
View Study & Checklist ➔Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
📍 Johns Hopkins Hospital — Baltimore, Maryland
NF1
View Study & Checklist ➔Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
📍 Clinical Pharmacology of Miami — Miami, Florida
Healthy
View Study & Checklist ➔Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Recurrent Chronic Lymphocytic Leukemia
View Study & Checklist ➔Mirdametinib in Histiocytic Disorders
📍 Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
Langerhans Cell Histiocytosis (LCH)
View Study & Checklist ➔A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
📍 University of Minnesota — Minneapolis, Minnesota
Primary Malignant Peripheral Nerve Sheath Tumors
View Study & Checklist ➔